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Tumor suppressor PTEN controls genomic stability
and inhibits tumorigenesis. The N-terminal phospha-
tase domain of PTEN antagonizes the PI3K/AKT
pathway, but its C-terminal function is less defined.
Here, we describe a knockin mouse model of a
nonsense mutation that results in the deletion of
the entire Pten C-terminal region, referred to as
PtenDC. Mice heterozygous for PtenDC develop
multiple spontaneous tumors, including cancers
and B cell lymphoma. Heterozygous deletion of the
Pten C-terminal domain also causes genomic insta-
bility and common fragile site rearrangement. We
found that Pten C-terminal disruption induces p53
and its downstream targets. Simultaneous depletion
of p53 promotes metastasis without influencing the
initiation of tumors, suggesting that p53 mainly
suppresses tumor progression. Our data highlight
the essential role of the PTEN C terminus in the
maintenance of genomic stability and suppression
of tumorigenesis.
INTRODUCTION
PTEN is one of the most frequently mutated genes in human
cancer (Li et al., 1997; Steck et al., 1997), and cancer-associ-
ated PTEN mutations are found scattered over the entire
PTEN gene (Song et al., 2012). The phosphatase domain
in the N-terminal region of PTEN is responsible for antago-
nizing the PI3 kinase (PI3K)/AKT pathway, the primary signaling
pathway for cell survival and proliferation (Maehama and Dixon,
1998). A large number of PTEN mutations occur in the C termi-
nus, suggesting that this region may also play a critical role in
tumor suppression. We previously demonstrated that the C-ter-
minal region is required for PTEN function in maintaining chro-
mosomal integrity (Shen et al., 2007). The C-terminal sequence
of PTEN is also important for its nuclear localization (Terrien
et al., 2012) and regulation of anchorage-independent growth
(Georgescu et al., 1999) and cell migration (Leslie et al., 2007).844 Cell Reports 6, 844–854, March 13, 2014 ª2014 The AuthorsThese findings suggest that C-terminal PTEN plays a significant
role in suppressing neoplasm.
In addition to somatic PTEN alterations in a variety of sporadic
tumor types, germline PTEN mutations are associated with
a range of hereditary tumor predisposition syndromes such
as Cowden syndrome (Marsh et al., 1998a, 1998b). Cowden
syndrome is an autosomal dominant disorder characterized by
multiple hamartomas and high risk of breast and thyroid cancers
(Farooq et al., 2010; Liaw et al., 1997). Genetic and clinical data
have been combined to interrogate howPTENmutations in Cow-
den syndrome increase cancer risk (Bubien et al., 2013; Marsh
et al., 1998a; Tan et al., 2012). Knockout of the Pten gene
in mice increases incidence of tumors that partially resemble
the spectrum of neoplasia in Cowden syndrome (Di Cristofano
et al., 1998; Podsypanina et al., 1999; Stambolic et al., 2000;
Suzuki et al., 1998). Moreover, knockin of mutant alleles that
affect PTEN phosphatase activity can cause distinct yet Cowden
syndrome-like tumor phenotypes (Wang et al., 2010).
The majority of germline PTEN mutations are nonsense or
frameshift mutations that result in premature stop codons and
C terminus truncations (Bubien et al., 2013; Marsh et al.,
1998a). According to a recent report, germline PTEN truncation
mutations preferentially target the C-terminal region and
comprise over 80% of the total mutations in this region (Bubien
et al., 2013). These data suggest that C-terminal PTEN
mutation or deletion may contribute to the cancer susceptibility
phenotype of Cowden syndrome. Among the variety of germline
truncated PTEN mutations identified in Cowden syndrome,
c.565A > T, a nonsense point mutation, is of particular interest
because it causes truncation at Arg189, resulting in loss of the
entire PTEN C-terminal region (DC).
In this study, wemodeled this nonsense point mutation inmice
to examine the role of the PTEN C terminus in tumor suppres-
sion. Pten+/DCmice exhibit chromosomal instability and develop
multiple tumors. We also found that the p53 signaling pathway is
activated in Pten+/DCmice and depletion of p53 in Pten+/DCmice
facilitates malignancy and promotes metastasis. These data
suggest that C-terminal PTEN functions to prevent tumorigen-
esis, whereas p53 acts mainly at later stages to suppress tumor
progression. Our study demonstrates that the PTEN C-terminal
region is essential for the maintenance of genomic stability and
suppression of tumor development.
Figure 1. Knockin of C-Terminal Truncated
Pten Reduces Mouse Lifespan because of
Spontaneous Tumor Development
(A) Schematic diagram of strategy for knockin
of the Pten point mutation, c.565A > T, leading
to deletion of the Pten C-terminal domain (aa
189–403).
(B) Confirmation of the point mutation of c.565A >
T by direct sequencing of Pten exon 6 in Pten+/+
and Pten+/DC ES clones.
(C) The expression of the C-terminal truncated
PtenDC in various tissues of Pten+/DC mice
examined by immunoprecipitation with an N-ter-
minal-specific PTEN antibody prior to FLAG
immunoblotting. Corresponding tissues fromwild-
type mice were included as controls.
(D) Kaplan-Meier plot for overall survival of Pten+/+
and Pten+/DC mice.
(E) Kaplan-Meier plot showing significantly shorter
latency of tumor development in Pten+/DC mice as
compared with wild-type control mice.
(F) Incidence of tumor in different tissues. Pten+/DC
mice aged from 12 to 60 weeks (n = 35, 14 males
and 21 females) were subjected to extensive his-
tological evaluation. Enlarged lymph nodes were
found in every mouse analyzed. Pheochromocy-
toma occurred in all Pten+/DC mice older than
6 months with a 12% frequency of pulmonary
metastasis.
See also Figure S1.RESULTS
Heterozygous Pten C-Terminal Deletion Causes Early
Mortality and Spontaneous Tumor Development in
Multiple Organs
To determine whether the C-terminal truncated PTEN mutation
gives rise to Cowden syndrome-like phenotypes, we generated
a mouse model by knocking in this point mutation (c.565A > T)
preceded by a FLAG tag (Figure 1A). Pten C-terminal truncation,
referred to as PtenDC, was confirmed in targeted embryonic stem
(ES) cells by Southern blot and DNA sequencing, and sub-
sequently in heterozygous mice by genotyping (Figures 1B,
S1A, and S1B). The C-terminal truncated Pten protein, PtenDC,
is expressed in various tissues in Pten+/DC mice (Figures 1C)
but not in Pten+/+ or Pten+/ mouse tissues (Figure S1C). We
observed reduced levels of Pten expression in tissues from
both Pten+/DC and Pten+/ mice, which results in elevated pAkt
levels only in some Pten+/ tissues. The majority of Pten+/DCCell Reports 6, 844–85tissues express comparable levels of
pAkt as counterpart Pten+/+ tissues (Fig-
ure S1D), indicating that there is a similar
level of phosphatase active Pten in
Pten+/DC mice as in wild-type cells. This
suggests that Pten+/DC mice contain a
phosphatase active PtenDC protein that
is capable of suppressing Akt phosphor-
ylation. To determine whether PtenDC
retains phosphatase activity, we over-
expressed this truncated protein inPten/MEFs. We found that PtenDC can reduce Akt phosphor-
ylation, whereas PTEN mutants lacking the N terminus (DN)
or phosphatase activity (C124S) fail to do so (Figure S1E). An
in vitro dephosphorylation assay further confirmed these
results (Figure S1F) and suggests that PtenDC retains the canon-
ical phosphatase activity of Pten.
In more than 50 litters, there were no viable homozygous
PtenDC mutant mice, suggesting that homologous deletion of
the Pten C terminus is lethal. In a cohort of 36 heterozygous
PtenDC mutation knockin mice (Pten+/DC) and 45 wild-type
control mice followed over 60 weeks for survival analysis, we
found that knockin of the PtenDC mutation leads to earlier death
(Figure 1D) mainly due to tumor formation inmultiple organs (Fig-
ures 1E and 1F).
Pten+/DC mice develop spontaneous tumors or demonstrate
premalignant lesions in multiple organs, including breast, thy-
roid, and endometrium, all of which show predisposition to
cancer in human Cowden syndrome (Pilarski, 2009). The primary4, March 13, 2014 ª2014 The Authors 845
Figure 2. Pten+/DC Mice Exhibit Cowden Syndrome-like Tumors in Multiple Tissues
(A) Benign and malignant mammary tumors. Top panels, complex mammary adenoma; middle and bottom-left panels, carcinoma with areas magnified to show
infiltrative growth of adipose tissue and skeletal muscle; bottom-right panel, gross view of a breast tumor with multiple foci of hemorrhagic necrosis.
(B) Follicular adenoma of the thyroid (left panels) and thyroid carcinoma (right panels). The carcinoma consists of a large expansile nodule. Selected areas of the
tumor are magnified to show follicular cells arrayed in disorderly, multilobulated nodules with atypia, and very little follicle formation reflecting lack of differen-
tiation in this carcinoma.
(C) A polyp of the large intestine showing features of a hamartomatous polyp shown in gross view (top, white arrow) and histological views (middle and bottom).
(D) Sebaceous adenoma of the skin consisting of a pseudoencapsulated expansile neoplasm showing features of skin appendage architecture.
(E) Endometrial epithelial hyperplasia with dysplasia showing endometrium expanded by moderate cystic dilation of endometrial glands and disorderly growth of
epithelial cells.
(F) Macrocephaly manifested by significantly increased brain weight in Pten+/DCmice as compared with age- and gender-matched wild-type control mice. ***p <
0.0001.
See also Figure S2.clinical concern in Cowden syndrome is elevated overall cancer
incidence, and the most affected organs are breast and thyroid
(Pilarski, 2009). Individuals with PTEN germline mutations have
an 85.2% lifetime risk for breast cancer and a 35.2% risk for846 Cell Reports 6, 844–854, March 13, 2014 ª2014 The Authorsthyroid cancer (Tan et al., 2012). Consistent with human Cowden
syndrome, breast and thyroid cancers are the most prominent
malignancies in Pten+/DC mice (Figures 1F, 2A, and 2B).
Mammary adenoma and carcinoma occur in female Pten+/DC
mice with frequencies of 28.6% and 9.5%, respectively (37.5%
and 12.5% in female mice older than 9 months). The frequency
of follicular thyroid adenoma in Pten+/DC mice is 35.5%, and
thyroid malignancy is found in 6.5% of PtenDC mutation knockin
mice. Five out of 21 Pten+/DC female mice (23.8%) develop both
mammary and thyroid tumors, and malignancy usually emerges
in 9–13.5 months. Diagnostic criteria of Cowden syndrome
also include macrocephaly and mental retardation, gastrointes-
tinal polyps, and mucocutaneous lesions (Farooq et al., 2010).
In addition to breast and thyroid cancers, intestinal polyps
occur in almost all Pten+/DC mice older than 7 months (Figures
1F and 2C). Pten+/DC mice also exhibit skin lesions such as
orthokeratotic hyperkeratosis or sebaceous adenoma (Fig-
ure 2D), as well as endometrial hyperplasia (Figure 2E) and
macrocephaly (Figure 2F). Knockin ofPtenDC, amutation derived
from Cowden syndrome patients, endows Pten+/DC mice with
all the characteristic phenotypes precisely imitating those in
human Cowden syndrome. Our PtenDC mutation knockin mice
therefore provide an exemplary animal model for Cowden
syndrome.
In addition to the typical phenotypes associated with Cowden
syndrome, Pten+/DC mice exhibit other abnormalities and
lesions, such as thyroid goiter, adrenal pheochromocytoma
with a 12% metastatic rate, polypoid adenoma of gallbladder
mucosa, prostatic intraepithelial neoplasia, and epididymitis as
shown in Figures S2A–S2E. The high incidence of neoplasm
particularly in the premalignant stage in Pten+/DCmice offers op-
portunity for investigation of genetic andmolecular events during
tumor development and progression.
Epithelial to mesenchymal transition (EMT) is associated with
acquisition of malignancy in epithelial tumor development (Nieto
and Cano, 2012; Scheel and Weinberg, 2012). We evaluated for
EMT in the development of breast cancer in Pten+/DC mice and
found that a typical transition from epithelium to mesenchyme
is indeed evident in mammary tissues at the adenoma stage.
As compared with normal breast tissue from wild-type mice,
mammary adenomas from Pten+/DC mice exhibit a significant
decrease in an epithelial marker, E-cadherin, with a simulta-
neous increase in expression of a marker for fibroblast-like cells,
FSP-1 (Figure S3A). These results suggest that heterozygous
deletion of the Pten C-terminal region may elicit malignancy
by promoting epithelial plasticity. A variant isoform of CD44,
CD44v6, has been implicated in tumor progression and
may induce mesenchymal and metastatic phenotypes (Zo¨ller,
2011). Breast tissues from Pten+/DC mice, particularly at the
adenoma stage, express significantly higher levels of CD44v6,
as compared with normal tissues from wild-type mice (Fig-
ure S3B). These mesenchymal phenotypes in Pten+/DC mice,
together with the widespread occurrence of pathological
changes in multiple tissues, suggest that the C-terminal
truncated Pten mutation may result in fundamental genomic
alterations.
Micewith the PtenC-Terminal Truncated Allele Develop
B Cell Lymphoma
Heterozygous deletion of the whole Pten gene can result in
development of lymphoma, but mice with heterozygous Pten
deletion develop only T cell lymphomas (Podsypanina et al.,1999; Stambolic et al., 2000; Suzuki et al., 1998). In contrast,
knockin of the Pten C-terminal truncated allele gives rise to
lymphomas of predominant B cell lineage in mice. Pten+/DC
mice also exhibit lymphoproliferative change in various sites.
Splenomegaly is often found associated with abnormal splenic
architecture, with expansion of white pulp and compression of
the red pulp (Figure 3A). This splenic expansion in Pten+/DC
mice involves B220+ B cells, resulting in displacement of CD3+
T cells, andmany regions with B cell expansion have a high index
of proliferation as measured by Ki67 staining (Figure 3B). Lym-
phocytic infiltration is also often found in nonlymphoid tissues
such as lung and kidney (Figure 3A). In lymph nodes and nonlym-
phoid tissues with lymphocytic infiltration, strong Ki67 signals
are found in regions of B cell expansion representing neoplasm
or preneoplastic change (Figures 3C and S4A). Bcl-6 is
frequently activated in B cell lymphomagenesis (Basso and
Dalla-Favera, 2010) and plays a causal role in development of
diffuse large B cell lymphoma (Cattoretti et al., 2005). In Pten+/DC
mice, Bcl-6 staining is found consistently in regions of B cell pro-
liferation (Figures 3B, 3C, and S4A), and these features together
are diagnostic of B cell lymphoma. Further analysis of clonality in
rearranged immunoglobulin (Ig) H genes from ten biopsies con-
firms these regions are clonal B cell expansions (Figure 3D).
These same biopsies also display a clonal rearrangement of
the TCR genes (Figure S4B), suggesting that lymphomas in
Pten+/DC mice are of mixed lineage.
Pten C-Terminal Haploinsufficiency Leads to
Chromosome Instability and Genomic Alterations
PTEN is critical for chromosome integrity and loss of Pten results
in centromere instability (Shen et al., 2007). In order to determine
whether C-terminal truncation of Pten also leads to centromere
instability, we performed cytogenetic analysis for potential
numerical and structural chromosome aberrations in our mouse
model. As expected, there is a significantly higher frequency of
tetraploidy in primary mouse embryonic fibroblasts (MEFs) with
heterozygous Pten C-terminal deletion, as compared to wild-
type MEFs (Figures 4A and 4B). Aneuploidy is found in Pten+/DC
MEFs but not in Pten+/+ cells. In addition to aberrant chro-
mosome numbers, Pten+/DC cells exhibit prominent structural
chromosome abnormalities. This is manifested by centromeric
aberrations such as centromeric fragments (CFs), acentric chro-
mosomes (ACs), premature centromeric separation (PCS), and
Robertsonian centromeric fusion (Rob), as shown in Figure 4C
and summarized in Figure 4D. Accordingly, the ability of PTEN
to physically interact with the integral centromere protein
CENP-C is impaired in Pten+/DC cells and tissues (Figure 4E).
We also compared the DNA damage status using gH2AX as a
DNA double-strand break (DSB) marker and found that Pten+/DC
MEFs carry a significantly increased frequency of DSBs as
compared with Pten+/+ or Pten/ cells (Figures S5A and S5B).
These data collectively suggest that the Pten C-terminal region
is important for maintaining numerical and structural stability of
the chromosome.
To further investigate genetic alterations caused by Pten
C-terminal truncation, we examined genome-wide copy number
changes using a comparative genomic hybridization array
(aCGH). The CGH array identified over 50 genes with copyCell Reports 6, 844–854, March 13, 2014 ª2014 The Authors 847
Figure 3. Pten+/DC Mice Develop Lymphoma Predominantly of B Cell Lineage
(A) Splenomegaly and lymphoma. The upper panel shows gross views of enlarged spleen (arrows point to amesenteric lymph node and nodular aggregates in the
spleen) in Pten+/DCmice. The lower panel displays histological images of abnormal splenic architecture (lowermiddle left) and lymphoma in the lung (lowermiddle
right) and kidney (lower right). Normal spleen from a wild-type mouse is shown (lower left) as a control.
(B) Lymphoma in the spleen from a Pten+/DC mouse. Immunohistochemical analysis of B (B220), T (CD3), proliferation (Ki67) cell markers, and Bcl-6 in spleens
from Pten+/+ and Pten+/DC mice.
(C) B cell lymphomawith strong expression of the Bcl-6 marker. Lymph nodes from Pten+/DCmice were subjected to immunohistochemical staining for indicated
cell markers.
(D) Validation of B cell lymphoma lineage derivation by clonality analysis. Clonal B cell expansion is identified by monotonous D-J rearrangement of IgH in ten out
of 12 biopsies (lanes 3–7, 9, 10, 12–15).
See also Figure S4.number variations, a subset of which is listed in Table S1. Two of
these genes, Fhit and Wwox, are located in chromosomal re-
gions prone to deletion and translocation known as common
fragile sites (Iliopoulos et al., 2006). Common fragile sites consti-848 Cell Reports 6, 844–854, March 13, 2014 ª2014 The Authorstute preferential targets for oncogenic chromosome damage
especially in preneoplastic lesions, and instability of these sites
represents a driving event in tumor development and progres-
sion (Gorgoulis et al., 2005; Tsantoulis et al., 2008). Altered
Figure 4. Knockin of PtenDC Causes Chro-
mosomal Instability
(A and B) Aneuploidy and polyploidy. Chromosome
number was examined in metaphase spreads
prepared from Pten+/+ (n = 101) and Pten+/DC (n =
126) MEFs (A) and data are summarized in the
histogram (B). Images shown above the histogram
are representative metaphase spreads. *p < 0.05;
**p < 0.01.
(C) Chromosomal aberrations featured by centro-
meric abnormalities. Metaphase spreads from
Pten+/+ (n = 32), Pten+/ (n = 48) and Pten+/DC (n =
43) MEFs were hybridized with a pan-centromeric
probe (yellow) and DNA was stained with propi-
dium iodide. Areaswith aberrant chromosomes are
magnified for visual enhancement. CF, centro-
meric fragment; AC, acentric chromosome frag-
ment; PCS, premature centromeric separation;
Rob, Robertsonian chromosomal fusion.
(D) A summary of frequencies of centromeric
fragments (CFs) and acentric chromosomes (AC, >
2 per cell).
(E) Loss of physical association with CENP-C.
Protein lysates from Pten+/+ and Pten+/DC cells or
tissues were immunoprecipitated with a PTEN
monoclonal antibody followed by immunoblotting
with a rabbit CENP-C antibody.
See also Figure S5.splicing and translocation of both Fhit and Wwox result in
abnormal transcripts, which occur frequently in multiple tumor
types and precancerous lesions (Huebner and Croce, 2001;
Matsuyama et al., 2004). In order to assess genetic alterations
in these fragile genes, we examined abnormal transcripts of
Fhit andWwox in different tissues from Pten+/DCmice. As shown
in Figures 5A and S6A, multiple aberrant Fhit and Wwox
transcripts are found in different Pten+/DC tissues. Direct
sequencing of these variant transcripts reveals multiple patterns
of rearrangement, including alternative splicing and segmental
deletion/insertion (Figures 5B–5D and S6B). For example, in
some adrenal and prostate tissues harboring the PtenDC allele,
a large segmental deletion removes exons 3–7 of Fhit and relo-
cates short sequence segments from upstream of the Fhit start
codon between exons 2 and 8 instead (Figures 5C and 5D). In
order to evaluatewhether these altered transcripts influence pro-
tein expression, we examined the levels of Fhit and Wwox in
various tissues from Pten+/+ and Pten+/DC mice. Both Fhit and
Wwox are downregulated in most tissues with PtenDC knockin,
as compared with counterpart wild-type tissues (Figures 5ECell Reports 6, 844–85and S6C). An additional faster migrating
protein band accompanies reduced
expression of Fhit in almost every tissue
from Pten+/DC mice (Figure 5E), which
is likely the product of aberrant tran-
scripts. Both FHIT and WWOX are tumor
suppressor genes and biomarkers of
genomic instability during early malignant
transformation (Aqeilan et al., 2007;
Iliopoulos et al., 2006; Pichiorri et al.,2008). Aberrant transcripts and deregulation of these genes sug-
gest that PtenDC knockin causes extensive genetic alterations
indicative of preneoplastic or neoplastic change. These results
suggest that genomic instability caused by this truncated Pten
mutant may be a driving force for tumorigenesis.
The p53 Pathway Is Upregulated in Pten+/DC Mice
p53 is the most frequently mutated genes in human cancer and
plays important roles in cell-cycle control, apoptosis and
genomic stability. It has been reported that PTEN deficiency
can activate p53 (Chen et al., 2005; Kim et al., 2007). In order
to determine whether Pten C-terminal deletion may activate
p53, we examined the levels of p53 in cells and tissues lacking
the Pten C-terminal region. Pten+/DC MEFs express a higher
level of p53 and accordingly, two well-known p53 transcrip-
tional targets, the apoptosis mediator Apaf1 and the cell-cycle
inhibitor p21, are both similarly induced (Figure 6A). Further
analysis in various Pten+/DC tissues also confirmed the
increased levels of p53 as compared to counterpart control
tissues from wild-type mice (Figure 6B). Immunohistochemistry4, March 13, 2014 ª2014 The Authors 849
Figure 5. Knockin of PtenDC Results in
Common Fragile Site Instability
(A–D) Aberrant transcripts of Fhit in different
tissues from Pten+/DC mice due to alternative
splicing and translocation. Transcripts of Fhitwere
amplified with nested PCR from cDNA of indicated
tissues (A) and abnormal transcripts were purified
for sequencing (B–D).
(E) Reduction of normal Fhit expression (17 kDa)
and production of a smaller Fhit protein variant
(15 kDa). Various pairs of tissues from Pten+/+
and Pten+/DC mice as indicated were analyzed for
Fhit expression by western blot.
See also Figure S6 and Table S1.analysis of p53 signaling illustrates that thyroid tissues from
Pten+/DC mice express elevated levels of p53, p21, and
Apaf1, as compared with wild-type mice (Figure 6C). These
data suggest that the p53 pathway is activated by heterozy-
gous Pten C-terminal loss, which may represent a defensive
response to genetic stress resulting from Pten C-terminal
deficiency.
Simultaneous Disruption of p53 and Pten C Terminus
Promotes Thyroid Tumor Progression
In order to determine whether depletion of p53 may enhance
tumor development in Pten+/DC mice, we generated p53 and
Pten C terminus dual-deficient (Pten+/DCp53+/) mice by
crossing Pten+/DC mice with p53+/ mice (Figure 7A). We found
that as compared with Pten+/DC mice, dual-deficient mice
develop similar types of tumors in comparable frequencies in
most tumor-prone organs except for thyroid gland (Figure 7B).
Malignant thyroid tumors occur at earlier ages (5 months versus
13 months) and higher frequencies (27.8% versus 6.5%) in850 Cell Reports 6, 844–854, March 13, 2014 ª2014 The Authorsdual-deficient mice than in single Pten
C-terminal-deficient mice.Moreover, thy-
roid tumor lung metastasis has been
observed only in Pten+/DCp53+/ mice
(Figure 7C), but not in Pten+/DC mice.
These observations suggest that p53
activation in Pten+/DC mice (Figure 6C)
plays an important role in preventing thy-
roid tumor progression and metastasis.
Other than the difference in thyroid tumor,
Pten+/DCp53+/ mice develop sarcoma
and T cell lymphoma, whereas no sar-
coma was found in Pten+/DC mice. Sin-
gle p53-deficient (p53+/) mice also
develop sarcoma and T cell lymphoma,
but at older ages (Donehower, 1996) as
compared with Pten+/DCp53+/ mice,
indicating that Pten C-terminal deficiency
facilitates tumor development in p53+/
mice. All these results demonstrate that
PTEN and p53 can collaborate with
each other in tumor suppression. Our
data suggest that p53 deficiency pro-
motes tumor progression at later stagesincluding metastasis in certain tumor types without affecting
the initiation of tumor development.
DISCUSSION
PTEN function in tumor suppression has been attributed primar-
ily to its phosphatase activity in antagonizing the PI3K/AKT
survival pathway (Simpson and Parsons, 2001). In this study,
we generated a mouse model in which the entire C-terminal
region of Pten is deleted. Data generated from our Pten+/DC
mice demonstrate that even in the presence of the intact
N-terminal phosphatase domain, heterozygous segmental
deletion of the Pten C terminus leads to a wide spectrum of
tumors. In addition to the identification of tumor phenotypes in
PtenDC knockin mice, our study reveals genetic and molecular
alterations that may drive tumor development. For example,
PtenDC knockin mice exhibit extensive genomic instability in
multiple organs manifested by common fragile site rearrange-
ment, representing an overall fragile genome susceptible to
Figure 6. Pten C-Terminal Deletion Induces
the p53 Signaling Pathway
(A) Upregulation of p53 and its downstream targets
in Pten+/DC MEFs as compared with wild-type
cells. Western blot analysis of p53 and its target
genes in Pten+/+ and Pten+/DCMEFs using specific
antibodies as indicated.
(B) p53 induction in various tissues lacking the
Pten C-terminal region. Various tissues from mice
with and without Pten C-terminal deletion were
subjected to immunoblotting analysis of p53
expression.
(C) Thyroid tissues from Pten+/+ and Pten+/DCmice
were stained by immunohistochemistry for p53,
p21, and Apaf1, showing increased signals in
PtenDC knockin tissues.genotoxic stress or DNA damage and subsequent neoplastic
transformation. Therefore, our data highlight the important role
of the PTEN C-terminal region in genomic stability and tumor
suppression and suggest that genomic instability is a driving
force of tumorigenesis.
One of the important features of Pten+/DC mice is that
neoplastic phenotypes emerge at different stages, ranging
from hyperplasia, dysplasia, and premalignancy to malignant
neoplasia. This mimics cancer susceptibility in Cowden
syndrome and offers the opportunity for tracking genetic and
molecular alterations occurring at different stages of tumor
development and progression. At the adenoma stage, PtenDC
knockinmammary tissues exhibit EMT, suggesting that epithelial
alteration may be an early manifestation of cellular deterioration,
leading to initiation of malignancy. Common fragile site rear-
rangement is often found in precancerous lesions and Fhit is
the most frequent target for allelic deletion and translocation
(Saldivar et al., 2010, 2012). Indeed, the expression of Fhit is
reduced in almost all tissues harboring the PtenDC allele, even
those without obvious features for neoplasm. Therefore, com-
mon fragile site instability may represent an early genetic trait
or genomic signature for cancer susceptibility.
Our study demonstrates that a PTEN germline mutation
associated with Cowden disease results in genetic instability
and cancer susceptibility in a mouse model. We found that
haploinsufficiency of the Pten C-terminal region results in a
series of phenotypes that encompassalmost all the characteristic
pathological features of Cowden syndrome. Thus, the PtenDCCell Reports 6, 844–85knockin mouse is a bona fide Cowden
syndrome model. Our PtenDC knockin
mouse not only successfully models hu-
man disease-associated truncation muta-
tions that predominantly disrupt the PTEN
C terminus, but also illustrates that PTEN
C-terminal haplosufficiency may shift the
genomic and tissue programming toward
cancer susceptibility.
Knockin of PtenDC not only disrupts
one Pten allele, but also creates a trun-
cated phosphatase active PtenDC protein,
which is distinct from existing Pten het-erozygous deletion animal models (Di Cristofano et al., 1998;
Podsypanina et al., 1999; Stambolic et al., 2000; Suzuki et al.,
1998). Gain of oncogenic function is an important feature of
mutation in a typical tumor suppressor. A comparison between
our Pten+/DC mouse model and different Pten+/ mouse strains
suggests that Pten+/DC mice develop tumors of various types
not only similar to those reported in Pten+/ strains, but we
also found some heretofore unidentified phenotypes such as B
cell lymphoma. Lymphoma development has been described
in mice with heterozygous Pten deletion (Podsypanina et al.,
1999; Stambolic et al., 2000; Suzuki et al., 1998). However, these
previously reported lymphomas are T cell type. Although a
reduction of PTEN expression has recently been correlated
with diffuse large B cell lymphoma in human samples (Pfeifer
et al., 2013), there is no evidence in any available model systems
to suggest a direct link between PTEN deficiency and B cell
lymphomagenesis. Even conditional deletion of Pten specifically
in B cells does not cause B cell lymphoma (Anzelon et al., 2003).
Most likely, loss of Pten is insufficient to induce lymphoma of
B cell lineage. Therefore, lymphomagenesis with clonal B cell
expansion in Pten+/DC mice represents a newly acquired pheno-
typic feature originated from Pten C-terminal truncation and
subsequent genomic instability. We propose that PtenDC is a
gain-of-function oncogenic mutation leading to a dominant
negative mutator phenotype, of which B cell lymphoma is only
one presentation.
PTEN and p53 are both powerful tumor suppressors. How-
ever, they may function at distinct stages to prevent tumor4, March 13, 2014 ª2014 The Authors 851
Figure 7. Inactivation of p53 in Pten+/DC
Mice Facilitates Malignancy and Promotes
Metastasis of Thyroid Tumors
(A) Generation of double-knockout mice with
heterozygous p53 and PtenDC alleles. Genotyping
PCR analysis of tail DNA from Pten+/+p53+/+,
Pten+/DCp53+/+, and Pten+/DCp53+/ mice.
(B) A summary of tumor incidence based on
extensive histological evaluation.
(C) Representative histological images showing
thyroid tumor metastasis in lung.development and progression. In our mouse models, dual defi-
ciency of both p53 and the Pten C terminus only promotes
thyroid tumor progression without affecting tumor initiation or
progression of other tumor types in mice with single Pten
C-terminal deficiency. These observations suggest that PTEN
deficiency contributes to the initial stage of tumor develop-
ment, whereas p53 mainly acts at later stages of tumor pro-
gression. Our data also suggest that p53 activation in Pten+/DC
mice may represent a defensive response to lack of Pten
function. Given that p53 mutation is very common in human
cancer, maintaining functional integrity of the p53 pathway
ensures a favorable response to cancer treatment. Therefore,
activation of the p53 pathway in response to Pten C-terminal
truncation may benefit future therapeutic studies using our
Pten+/DC mice.
This study establishes the important role of C-terminal PTEN
in genomic stability and tumor suppression. Our work also
reveals early genetic andmolecular alterations, such as common
fragile site instability and EMT, which contribute to tumorigen-
esis and malignancy. Data obtained from PtenDC knockin mice
provide insight into the process of cellular transformation in
which a driver mutation leads to systemic genomic instability
and tumorigenesis. Moreover, the p53 pathway is activated in
our Pten C-terminal truncated mice, which suggests that this
mouse model would be ideal for preclinical trials of chemothera-
peutic compounds to treat human cancers or cancer predisposi-
tion diseases.852 Cell Reports 6, 844–854, March 13, 2014 ª2014 The AuthorsEXPERIMENTAL PROCEDURES
Mice
To generate Pten C-terminal truncation (PtenDC)
knockin mice, C57BL6/129S6 mouse ES cells
were electroporated with targeting vectors con-
taining a 50 homology region with Pten exons 4-5,
a neo cassette flanked by two loxP sites (LoxP-
Neo-LoxP), and a 30 homology region containing
exon 6 with the desired mutation. ES cells were
selected by G418 and screened for homologous
recombination by PCR. Southern blot was used
to further identify PtenDC knockin ES clones. Posi-
tive targeted ES clones containing the targeted
allele with desired FLAG and stop codon replace-
ment were injected into C57BL/6 blastocysts, and
the blastocysts were implanted into pseudopreg-
nant females to generate chimeras. The chimeras
were bred with EIIA-Cre transgenic female mice
to delete the loxP-flanked neomycin resistance
gene (neo) from the targeted allele. The resultantneo-deleted mosaic Pten+/DC mice were genotyped by PCR. Positive mosaic
mice were crossed with the C57BL/6 strain to generate heterozygous mice.
To further validate FLAG and stop codon replacement in Pten+/DC mice, we
sequenced Pten mRNA from the original ES cells to confirm the knockin.
The offspring were PCR genotyped using a primer set (forward, 50-GCCTAT
CAGGGAGTCACAATTC-30; reverse, 50-AAAGTTTTCCGACACACAGACA-30 ).
p53+/ mice (B6.129S2-Trp53tm1Tyj/J) were purchased from the Jackson
Laboratory. Double-heterozygous Pten+/DCp53+/ mice were generated by
crossing Pten+/DC mice with p53+/ mice. This study and all procedures
were conducted in accordance with Weill Cornell Medical College Institutional
Review Board guidelines.
Primary MEF Cells
Primary MEFs were isolated from embryos harvested at 13.5 days after coitus.
Individual embryos were minced and digested by trypsin, and embryonic
cells were collected by centrifugation before plating in MEM supplemented
with 10% fetal bovine serum. MEFs from each embryo were genotyped as
described above and early passage cells were used for chromosomal analysis.
Histopathology and Immunohistochemistry
Animals were sacrificed or autopsied and all tissues were examined regardless
of their pathologic status. Tissue samples were fixed in 10% buffered formalin
and embedded in paraffin for preparation of 5 mm sections. Sections were
stained with hematoxylin and eosin (H&E) by standard methods. For immuno-
histochemistry, tissue sections were processed for immunohistochemical
evaluation of B220, CD3, Ki67, Bcl6, E-cadherin, FSP1, or CD44v6 following
standard procedures.
Antibodies
Polyclonal antibodies against mouse Fhit and Wwox were produced by immu-
nizing rabbits with specific peptides DELQKHDREEEDSPAFWC (aa 115–131
of Fhit) and CTVDDNPTKPTTRQRYDG(Amd) (aa 93–109 of Wwox). Antisera
from the immunized rabbits were affinity purified using their respective
peptides.
Centromeric Fluorescent In Situ Hybridization
Metaphase spreads were prepared from early passage (less than three) MEFs
and centromeric fluorescent in situ hybridization (C-FISH) was performed
using a fluorescein-isothiocyanate-labeled pan-centromeric probe (Cambio)
following the procedures described previously (Shen et al., 2007). DNA was
counterstained with propidium iodide.
Comparative Genomic Hybridization Array
Genomic DNA extracted from Pten+/+ and Pten+/DC MEFs was subjected to
oligonucleotide array-CGH using Agilent SurePrint G3 mouse 1 3 1M CGH
microarrays, following the manufacturer’s instructions. These arrays include
963261 probes with a 1.8 kb overall median probe space. Hybridized slides
were scanned using a microarray scanner (G2505B, Agilent), and the image
data were extracted and converted to text files using Agilent Feature Extrac-
tion software. Following data normalization, segmentation, and analysis, seg-
ments with log2 ratios higher than 0.2 or lower than 0.2 were selected and
analyzed for copy number variation.
Common Fragile Site Aberrant Transcripts Analysis
RNA was prepared from different tissues of Pten+/+ and Pten+/DC mice
andcDNAwassynthesizedby reverse transcription.NestedPCRwasperformed
to amplify transcripts of Fhit or Wwox using the following primers: mFhit-1F,
CTTGCCTTTCATTCCAGC; mFhit-9R, GGGGTCCATTTTCTTAT; mFhit-2F,
TGAAGCCCAGCAAAGAAG; mFhit-8R, AAAGTAGACCCGCAGAGC; mWwox-
1F, TTGAAGCCAGAGTGAGTTGCTAG; mWwox-9R, GATGGGGCTGACTG
TGATGAGG; mWwox-2F, AAAACCGGCAAGAGGAAACG; and mWwox-
8R, GTTATAAGCCAGCATGGCCC. Abnormal transcripts were purified and
sequenced.
Clonality Analysis
Genomic DNA was prepared from different tissues of Pten+/+ and Pten+/DC
mice. Clonal rearrangement of the IgH segment (DSFL, B cell lineage) or
TCRg chain segment (VgH10, T cell lineage) was amplified by PCR using
the following primers: DSFL forward, 50-AG GGATCCTTGTGAAGGGATCT
ACTACTGTG-30; DSFL reverse, 50-AAAGACCTGCAGAGGCCATTCTTACC-
30; VgH10 forward: 50-AAGCAACAAAGTGGAGGCAAGAAAG-30; VgH10
reverse: 50-GAAGTTACTATGAGCTTAGTCCCTT-30.
Statistics
Overall and tumor-free survival curves were calculated with the Kaplan-Meier
method and analyzed with Gehan-Breslow-Wilcoxon test for statistical signif-
icance. Brain weight was measured in different age and gender groups, and
the paired t test was used to analyze differences between Pten+/DC and
Pten+/+ mice in each littermate group. Chromosome numbers and mitotic
indices were compared using Pearson’s chi-square test (c2). All statistical
tests were two-sided and p values less than 0.05 (*), 0.01 (**), or 0.0001 (***)
were considered statistically significant.
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